Loading...
XNAS
CYPH
Market cap28mUSD
Jul 09, Last price  
0.70USD
1D
7.53%
1Q
-33.96%
IPO
-99.11%
Name

Leap Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:CYPH chart
P/E
6.01
P/S
—
EPS
0.12
Div Yield, %
—
Shrs. gr., 5y
64.13%
Rev. gr., 5y
0.00%
Revenues
0k
00000009,680,00010,053,0001,500,0000000
Net income
5m
P
-7,756,000-18,324,000-25,451,000-21,103,000-25,632,000-29,727,000-23,138,000-3,446,000-3,387,000-40,587,000-54,596,000-81,414,000-67,555,0004,822,000
CFO
-44m
L-27.19%
-7,550,000-9,939,000-18,017,000-19,580,000-25,337,000-22,137,000-26,033,000-26,902,000-25,957,000-35,157,000-49,044,000-43,753,000-60,299,000-43,902,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Leap Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing treatments for various cancers. At the forefront of its pipeline is DKN-01, a monoclonal antibody designed to block Dickkopf-related protein 1 (DKK1). This investigational therapy is currently undergoing several clinical trials, targeting a range of malignancies such as esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics has also forged an option and licensing partnership with BeiGene, Ltd., granting them rights to develop and market DKN-01 across Asia (excluding Japan), Australia, and New Zealand. Established in 2011, the company initially operated as HealthCare Pharmaceuticals, Inc., before rebranding to Leap Therapeutics, Inc. in November 2015. Its corporate headquarters are situated in Cambridge, Massachusetts.
URL
https://www.leaptx.com/
IPO date
Jan 24, 2017
Employees
44
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT